Allurion Technologies Hits 52-Week Low at $1.35 Amid Financial Struggles

Allurion Technologies, Inc., a microcap company in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 1.35 as of November 11, 2025. This significant decline reflects a staggering 94.99% drop in the company's stock price over the past year, contrasting sharply with the S&P 500's performance of 13.96% during the same period.
The company's market capitalization stands at approximately USD 17 million, indicating its small size within the industry. Allurion Technologies has reported a negative book value, which raises concerns about its long-term financial stability. The company's ability to service its debt is also under scrutiny, highlighted by a poor EBIT to Interest ratio of -13.96.

In its latest financial results, Allurion reported net sales of just USD 3.38 million, marking a low point for the company. Additionally, raw material costs have increased by 11.18% year-over-year, further straining its financial position. With a negative EBITDA and a history of underperformance against the S&P 500, Allurion Technologies continues to face significant challenges in the current market landscape.